Company Filing History:
Years Active: 1997-2001
Title: Inventor Jeffrey J. Seilhammer: Pioneering Immunotherapy Innovations
Introduction
Jeffrey J. Seilhammer is an accomplished inventor based in Milpitas, CA, who has made significant contributions to the field of immunotherapy through his innovative pharmaceutical compositions. With a total of three patents to his name, Seilhammer's work primarily focuses on methods of selectively immunosuppressing the immune response and targeted drug delivery.
Latest Patents
One of Seilhammer's latest patents is titled "Method of Causing Selective Immunosuppression Using HL-60-Related Lectins". This invention outlines a pharmaceutical composition that is effective in treating autoimmune conditions. The active ingredient is a soluble lectin with a molecular weight of approximately 14 kilodaltons, which can bind to β-galactoside-containing moieties and stimulate hemagglutination in standard lectin assays. This composition can be utilized for conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, and may also modulate immune responses during allergic reactions or organ transplant rejections. Furthermore, it can be combined with general immunosuppressants for enhanced therapeutic efficacy.
In another significant patent, "Method of Delivering Drugs to Cells Specific for an HL-60 Lectin," Seilhammer outlines a method for drug delivery using a lectin-drug complex. This approach entails coupling a lectin to a drug, allowing for targeted administration to specific cells, thereby improving the efficacy of treatments for autoimmune diseases.
Career Highlights
Seilhammer's career is marked by his pivotal role at Incyte Pharmaceuticals, Inc., where he applies his expertise in immunology to develop cutting-edge therapies. His innovations are not only important for their scientific merit but also have the potential to significantly improve patient outcomes in the treatment of complex autoimmune disorders.
Collaborations
Throughout his career, Seilhammer has collaborated with esteemed colleagues, including Glenn E. Nedwin and Tim Bringman. This teamwork exemplifies the collaborative spirit often necessary in the field of pharmaceutical research and development, allowing for shared insights and advancements.
Conclusion
Jeffrey J. Seilhammer's contributions to immunometry represent a vital set of advancements in medical science. His inventive methodologies and compositions hold promise for revolutionizing treatment protocols for autoimmune conditions, showcasing the impact that dedicated inventors can have on healthcare. Through his ongoing work at Incyte Pharmaceuticals, Inc., Seilhammer continues to pioneer innovative solutions that may shape the future of immunotherapy.